Combination therapies in oncology - the developments regarding added benefit and costs during the first 5 years of early benefit assessment

被引：0

|

作者：

Schubert, A. ^{[1
]}

Tebinka-Olbrich, A. ^{[1
]}

Zentner, A. ^{[1
]}

Haas, A. ^{[1
]}

机构：

[1] GKV Spitzenverband Arznei & Heilmittel, Berlin, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P945

引用

收藏

页码：290 / 290

页数：1

相关论文

共 3 条

[1] ONCOLOGICAL COMBINATION THERAPIES IN THE CONTEXT OF THE EARLY BENEFIT ASSESSMENT ACCORDING TO AMNOG: STATUS QUO AND QUO VADIS
Fisenkci, N.
Boehler, Y. B.
VALUE IN HEALTH, 2023, 26 (12) : S365 - S366
[2] Kindergarten assessment policies and reading growth during the first two years: Does standardized assessment policy benefit children who are left behind?
Im, Haesung
LEARNING AND INDIVIDUAL DIFFERENCES, 2021, 86
[3] Budget Impact in Early Benefit Assessment Differences between Pharmaceutical Manufacturer's Dossiers and Corresponding IQWiG Assessments Regarding the Calculation of Target Population Size and Annual Therapy Costs of New Drugs
Schellhorn, H.
Zerwes, U.
Rosery, H.
GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2013, 18 (04): : 180 - 185